Published in Mod Pathol on September 10, 2010
Molecular analysis of thymoma. PLoS One (2012) 0.90
A gene signature to determine metastatic behavior in thymomas. PLoS One (2013) 0.84
Clinicopathological analysis of 241 thymic epithelial tumors-experience in the Shanghai Chest Hospital from 1997-2004. J Thorac Dis (2016) 0.83
Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c. Front Oncol (2013) 0.80
Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. Mod Pathol (2015) 0.80
Solitary metastasis to the breast after complete resection of encapsulated type AB thymoma: a case report. J Med Case Rep (2015) 0.79
The enlightenments from ITMIG Consensus on WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Dis (2016) 0.78
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. Br J Cancer (2016) 0.75
Unusual clinical behaviour of thymoma with recurrent myasthenia gravis. Interact Cardiovasc Thorac Surg (2012) 0.75
Malignant thymoma with metastasis associated with paraneoplastic myasthenia gravis. Proc (Bayl Univ Med Cent) (2017) 0.75
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol (2003) 3.58
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat (2009) 2.85
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg (2004) 2.29
Carboplatin for stage I seminoma and the sword of Damocles. J Clin Oncol (2005) 2.25
National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc (2002) 2.20
A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett (2007) 2.08
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol (2009) 2.08
Molecular profiling assays in breast cancer: are we ready for prime time? Oncology (Williston Park) (2012) 2.04
Optimum lymphadenectomy for esophageal cancer. Ann Surg (2010) 2.01
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow. Exp Hematol (2002) 1.88
Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol (2005) 1.86
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat (2007) 1.75
Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol (2008) 1.69
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2002) 1.67
Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol (2005) 1.65
SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer (2010) 1.56
Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.56
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat (2011) 1.46
ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Cancer Biol Ther (2010) 1.44
Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther (2009) 1.44
Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis (2009) 1.43
Surgical management of pulmonary and mediastinal sequelae of histoplasmosis: a challenging spectrum. Ann Thorac Surg (2009) 1.40
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol (2011) 1.40
Superficial temporal artery pseudoaneurysm: diagnosis and preoperative planning with CT angiography. AJNR Am J Neuroradiol (2003) 1.40
Standard outcome measures for thymic malignancies. J Thorac Oncol (2010) 1.39
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol (2011) 1.36
A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. Am J Clin Oncol (2011) 1.35
Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer (2008) 1.34
FOXA1 as a therapeutic target for breast cancer. Expert Opin Ther Targets (2007) 1.34
The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther (2005) 1.33
Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer (2003) 1.31
Extrathoracic metastases of thymic origin: a review of 35 cases. Mod Pathol (2011) 1.29
Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol (2011) 1.28
Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.27
FOXA1 in breast cancer. Expert Rev Mol Med (2009) 1.23
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res (2006) 1.23
AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Mol Cell Biol (2008) 1.21
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab (2007) 1.18
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer (2005) 1.18
FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat (2011) 1.17
Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis (2007) 1.16
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest (2007) 1.16
Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res (2006) 1.16
NuMA influences higher order chromatin organization in human mammary epithelium. Mol Biol Cell (2006) 1.14
Gastrointestinal stromal tumors: clinical, radiologic, and pathologic features. AJR Am J Roentgenol (2005) 1.13
A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci U S A (2006) 1.13
Thymoma and thymic carcinoma: therapeutic approaches. Clin Lung Cancer (2004) 1.11
Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res (2003) 1.10
Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys (2009) 1.09
Morphological changes in breast tissue with menstrual cycle. Mod Pathol (2002) 1.08
Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat (2006) 1.08
Role of AKT isotypes in breast cancer. J Pathol (2013) 1.07
High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology (2011) 1.07
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat (2012) 1.07
Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg (2012) 1.07
Pregnancy after breast cancer: if you wish, ma'am. Breast Cancer Res Treat (2011) 1.07
Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res (2011) 1.05
Towards large-scale histopathological image analysis: hashing-based image retrieval. IEEE Trans Med Imaging (2014) 1.05
Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat (2006) 1.04
Computerized classification of intraductal breast lesions using histopathological images. IEEE Trans Biomed Eng (2011) 1.02
Spindle cell lipoma of the oral cavity. Am J Dermatopathol (2006) 1.02
Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. Mod Pathol (2006) 1.02
ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res (2013) 1.00
Prognostic indicators after surgery for thymoma. Ann Thorac Surg (2010) 1.00
Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol (2006) 1.00
PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci (2011) 1.00
Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist (2011) 1.00
Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg (2010) 0.99
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat (2012) 0.99
Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being--a Hoosier Oncology Group Study. J Clin Oncol (2003) 0.98
Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol (2011) 0.98
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer (2007) 0.98
Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol (2004) 0.98
Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol (2012) 0.96
Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol (2009) 0.96
Support service use and interest in support services among distressed family caregivers of lung cancer patients. Psychooncology (2012) 0.95
The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis (2005) 0.95